AI Verdict
KAI has stronger fundamentals based on our AI analysis.
KAPA vs KAI Fundamental Comparison
| Metric | KAPA | KAI |
|---|---|---|
| Revenue | N/A | $1.1B |
| Net Income | $-5.4M | $102.0M |
| Net Margin | N/A | 9.7% |
| ROE | -85.9% | 10.4% |
| ROA | -83.3% | 6.0% |
| Current Ratio | 27.07x | 2.38x |
| Debt/Equity | 0.00x | 0.38x |
| EPS | $-0.30 | $8.65 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
KAPA vs KAI: Frequently Asked Questions
Is KAPA or KAI a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), KAI has stronger fundamentals. KAPA is rated SELL (85% confidence) while KAI is rated HOLD (72% confidence). This is not investment advice.
How does KAPA compare to KAI fundamentally?
Kairos Pharma, LTD. has ROE of -85.9% vs KADANT INC's 10.4%. Net margins are N/A vs 9.7% respectively.
Which stock pays higher dividends, KAPA or KAI?
KAPA has a dividend yield of N/A or no dividend while KAI has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in KAPA or KAI for long term?
For long-term investing, consider that KAPA has SELL rating with 85% confidence, while KAI has HOLD rating with 72% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about KAPA vs KAI?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For KAPA vs KAI, the AI consensus favors KAI based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.